ProfileGDS5678 / 1416749_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 87% 86% 89% 91% 87% 86% 89% 92% 93% 91% 84% 89% 87% 85% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.5899287
GSM967853U87-EV human glioblastoma xenograft - Control 26.5199686
GSM967854U87-EV human glioblastoma xenograft - Control 37.0580389
GSM967855U87-EV human glioblastoma xenograft - Control 47.5811591
GSM967856U87-EV human glioblastoma xenograft - Control 56.7441387
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.2797786
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.7670989
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.6588492
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.8712693
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.4666691
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.1879684
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.0654689
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.6183487
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.3633985